Running head: ACCELEROMETRY REFERENCE VALUES

- 1 Reference values for cut-point-free and traditional accelerometer metrics and
- 2 associations with cardiorespiratory fitness: a cross-sectional study of healthy adults
- 3 **aged 20 to 89 years**
- 4 Schwendinger F.^{1*}, Wagner J.¹, Knaier R.¹, Infanger D., Rowlands A.V.^{2,3,4}, Hinrichs T.¹, &
- 5 Schmidt-Trucksäss A.^{1*}
- 6 Division of Sports and Exercise Medicine, Department of Sport, Exercise and Health,
- 7 University of Basel, Basel, Switzerland
- 8 ² Assessment of Movement Behaviours Group (AMBer), Diabetes Research Centre, Leicester
- 9 General Hospital, University of Leicester, Gwendolen Rd, Leicester, UK
- ³ National Institute for Health Research (NIHR) Leicester Biomedical Research Centre
- 11 (BRC), University Hospitals of Leicester NHS Trust and the University of Leicester,
- 12 Leicester, UK
- ⁴ Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute for
- 14 Health Research, Division of Health Sciences, University of South Australia, Adelaide,
- 15 Australia

16

- 17 Jonathan Wagner (JW), jonathan.wagner@unibas.ch; ORCID: 0000-0002-3436-588X
- 18 Raphael Knaier (RK), raphael.knaier@unibas.ch; ORCID: 0000-0002-0244-7768
- 19 Denis Infanger (DI), denis.infanger@unibas.ch; ORCID: 0000-0001-9028-7110
- 20 Alex V. Rowlands (AVR), alex.rowlands@leicester.ac.uk; ORCID: 0000-0002-1463-697X
- 21 Timo Hinrichs (TH), timo.hinrichs@unibas.ch; ORCID: 0000-0001-6200-307X
- 22 * Correspondence:
- Fabian Schwendinger (FS), fabian.schwendinger@unibas.ch; ORCID: 0000-0001-7795-1478
- 24 Arno Schmidt-Trucksäss (AST), arno.schmidt-trucksaess@unibas.ch; ORCID: 0000-0002-
- 25 4662-3911

26

28

- 27 Abstract word count: 250
- 29 Manuscript word count: 2907

ACCELEROMETRY REFERENCE VALUES

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Abstract **Objectives:** To compare the association between cardiorespiratory fitness (CRF) and cutpoint-free accelerometer metrics (intensity gradient [IG] and average acceleration [AvAcc]) to that with traditional metrics in healthy adults aged 20 to 89 years and patients with heart failure, and 2) provide age-, sex-, and CRF-related reference values for healthy adults. **Methods**: In the COmPLETE study, 463 healthy adults and 67 patients with heart failure wore GENEActiv accelerometers on their non-dominant wrist and underwent cardiopulmonary exercise testing. Cut-point-free (IG: distribution of intensity of activity across the day; AvAcc: proxy of volume of activity) and traditional (moderate-to-vigorous and vigorous activity) metrics were generated. The 'rawacceleration' application was developed to translate findings into clinical practice. **Results**: IG and AvAcc yield complementary information on PA with both IG (p=0.009) and AvAcc (p<0.001) independently associated with CRF in healthy individuals. Only IG was independently associated with CRF in patients with heart failure (p=0.043). The best cutpoint-free and cut-point-based model had similar predictive value for CRF in both cohorts. However, unlike traditional metrics, IG and AvAcc are comparable across populations and the most commonly used accelerometers. We produced age- and sex-specific reference values and percentile curves for IG, AvAcc, moderate-to-vigorous, and vigorous activity for healthy adults. Conclusions: IG and AvAcc are strongly associated with CRF and, thus, indirectly with the risk of non-communicable diseases and mortality in healthy adults and patients with heart failure. Our reference values enhance the utility of cut-point-free metrics and facilitate their interpretation.

Trial registration: This study was registered on clinicaltrials.gov (NCT03986892).

ACCELEROMETRY REFERENCE VALUES

Keywords: accelerometry, physical activity, normative data, cardiorespiratory fitness, GGIR, activity monitors

- What is already known on this topic Cut-point free accelerometer metrics are
 valuable to assess physical activity because of their comparability across populations
 and association with various health parameters (e.g. body fat content or physical
 functioning). Yet, their interpretation is not straightforward.
- What this study adds This study found a strong and independent association of cut-point-free metrics with cardiorespiratory fitness, a vital sign, in healthy individuals aged between 20 to 89 years and patients with heart failure. We produced the first reference values based on healthy individuals across the age span.
- How this study might affect research, practice or policy Our reference values together with the new open-source application may simplify the interpretation of cut-point-free accelerometer metrics and their use in clinical practice and research.

ACCELEROMETRY REFERENCE VALUES

INTRODUCTION

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

Accelerometer data can yield many physical activity (PA) outcomes.[1] Recorded acceleration is often categorised using accelerometer cut-points and expressed as minutes spent in intensity categories, i.e. light, moderate, and vigorous PA.[2] Numerous studies have proposed such cut-points for different populations.[3, 4] Although this method makes accelerometer data interpretable, the multitude of available cut-points complicates the interpretation of PA data and comparison between studies. Moreover, using cut-points to quantify the absolute intensity of PA has been shown to induce bias if cardiorespiratory fitness (CRF) of the cohort of interest differs from the cohort the cut-points were derived from.[5] To circumvent this problem, Rowlands et al. (6) proposed cut-point-free accelerometer metrics, namely intensity gradient (IG) and average acceleration (AvAcc) and demonstrated their use across diverse populations. They moreover demonstrated the added value of using IG by examining the relation to body fatness and physical function.[6] IG was inversely associated with body fatness in adolescent girls and positively associated with physical function in adults with type 2 diabetes, independent of AvAcc.[6] The authors concluded that IG and AvAcc are appropriate for reporting as standardised measures and suitable for comparison across studies using raw-acceleration accelerometers.[6] The independent association of IG with health indicators (BMI z-scores, waist-to-height ratio, estimated CRF, and metabolic syndrome score) was later confirmed in children.[7] CRF, measured as peak oxygen uptake (VO_{2peak}), is a strong, independent risk predictor for various non-communicable diseases and all-cause mortality.[8] Data on the relationship between cut-point-free accelerometer metrics and CRF in healthy adults or diseased

populations e.g. patients with heart failure would therefore be relevant. Moreover, IG and

ACCELEROMETRY REFERENCE VALUES

115

91 AvAcc are not readily interpretable.[6] Reference values providing a framework for judging 92 the appropriateness of PA levels are required.[6] 93 Thus, we aimed to 1) examine the relationship between cut-point-free and traditional 94 accelerometer metrics, 2) compare the association between VO_{2peak} and cut-point-free metrics 95 to that with traditional metrics in healthy individuals and patients with heart failure, and 3) 96 produce reference values for cut-point-free and traditional accelerometer parameters for 97 healthy adults. 98 99 100 **METHODS** 101 Study design 102 Data were collected in the population-based, cross-sectional COmPLETE study at the 103 Department of Sport, Exercise and Health at the University of Basel, Switzerland. The study 104 protocol is available elsewhere.[9] All procedures were performed according to the 105 Declaration of Helsinki. The study was registered on clinicaltrials.gov (NCT03986892) and 106 approved by the Ethics Committee of North-western and Central Switzerland (EKNZ 2017-107 01451). 108 109 **Study participants** 110 The COmPLETE study examined healthy adults (HEALTHY) and patients with chronic heart 111 failure (HEART). HEALTHY were ≥20 years of age, non-smoking, and had a BMI <30 112 kg/m².[9] Exclusion criteria were the presence of chronic exercise-limiting disease, known 113 pregnancy or breastfeeding, hypertonic blood pressure >160/100 mmHg, orthopaedic 114 problems hindering the examinations, inability to follow the study procedures, and

contraindications for all-out exercise.[9] Individuals aged ≥20 years and diagnosed with

ACCELEROMETRY REFERENCE VALUES

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

stable chronic heart failure were eligible for HEART.[9] All exclusion criteria and a rationale for the study size are presented elsewhere.[9] **Study procedures** Accelerometry and data processing Participants were asked to wear a triaxial accelerometer (GENEActiv, Activinsights Ltd., Kimbolton, UK) on their non-dominant wrist, for 24 hours/day over 14 days.[9] Data were sampled at 50 Hz. Days with wear time >14 hours were considered valid. Participants needed to have at least four valid weekdays (Monday to Friday) and one Saturday and Sunday each.[5] Raw-data processing using the GGIR package[10, 11] is described in detail in the Supplement. Cardiopulmonary exercise testing Gas exchange was measured breath-by-breath during a graded exercise test on a cycle ergometer using the MetaMax 3B portable metabolic system (Cortex Biophysik GmbH, Leipzig, Germany). One of five ramp protocols was chosen depending on the participant's estimated CRF.[9] VO_{2peak} was recorded as the three highest consecutive values (30 s average) during the test. Detailed information are presented elsewhere.[12] **Statistical analyses** Statistical analyses and figures were done in R version 4.2.0.[13] Correlations between accelerometer parameters and VO_{2peak} were analysed using Spearman's Rank Correlation. Explorative principal component and partial least squares analyses were performed to examine the relationship between the abovementioned variables.[14, 15] Multiple linear regression models were used to examine between-cohort differences and the association

ACCELEROMETRY REFERENCE VALUES

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

between VO_{2peak} and accelerometer parameters, i.e. IG, AvAcc, MVPA, VPA and time in PA (TPA=light PA+MVPA). For each cohort, we planned to create three models with cut-pointfree metrics only (IG, AvAcc, and both parameters together), two models with cut-pointbased metrics only (MVPA and VPA), and two models containing IG or VPA as a measure of PA intensity and TPA as a surrogate of time in PA. All models were adjusted for age and an interaction between BMI and sex. We used restricted cubic splines with four knots placed at appropriate percentiles of the data for age and BMI.[16] Fulfilment of model assumptions was verified using residual diagnostics. The best model fit was selected based on residual standard deviation and adjusted R². A Likelihood-Ratio-Test was used to compare models. Non-nested models were compared using the Vuong Test.[17] Percentile curves were created with Generalised Additive Models for Location, Scale, and Shape with the GAMLSS package (version 5.3-4).[18] Age or VO_{2peak} as the independent parameter was fitted using psplines.[19, 20] We adopted the Bayesian information criterion to select the conditional distribution offering the best compromise between model complexity and goodness-of-fit. Model fits were inspected using diagnostic residual plots.[21] We developed the application 'rawacceleration' using 'shiny' [22] to translate our findings into clinical practice. The level of statistical significance was set at 0.05. All tests were two-sided.

RESULTS

679 HEALTHY and 89 HEART were invited to this study. Of those, 585 HEALTHY and 70

HEART fulfilled all criteria. After excluding participants with missing covariate data, 463

HEALTHY and 67 HEART were analysed. Cohort characteristics are presented in Table 1.

*** insert Table 1 here ***

Table 1. Characteristics of healthy individuals and patients with heart failure stratified by sex.

Variable	HEALTHY (<i>n</i> =463)	HEART (<i>n</i> =67)

ACCELEROMETRY REFERENCE VALUES

	Females	Males	Females	Males
n (%)	221 (47.7)	242 (52.3)	15 (22.4)	52 (77.6)
Age, years, [range]	55 (36, 71) [20 to 89]	55 (37, 71) [20 to 89]	74 (63, 79) [26 to 89]	65 (56, 75) [31 to 85]
Height, cm	165.3 (6.9)	177.4 (7.1)	160.5 (4.1)	175.4 (5.8)
Body mass, kg	62.0 (8.1)	77.4 (9.3)	71.2 (16.4)	87.4 (14.9)
Body mass index, kg·m ⁻²	22.7 (2.7)	24.6 (2.4)	27.6 (6.1)	28.4 (4.2)
Smoking status, n (%)				
Smokers	0	0	0	5 (9.6)
Never smoked	177 (80.1)	191 (78.9)	9 (60)	24 (46.2)
Ex-smoker > 10 years	44 (19.9)	50 (20.7)	2 (13.3)	20 (38.5)
NYHA class, n (%)				
I	0	0	2 (13.3)	29 (55.8)
II	0	0	6 (40.0)	13 (25.0)
III	0	0	7 (46.7)	10 (19.2)
Non-wear time, % of day	0.3 (1.0)	0.4 (1.3)	0.1 (0.2)	0.5 (2.2)
Waking time, h per day	16.2 (0.8)	16.3 (0.9)	15.7 (1.4)	16.2 (1.2)
Intensity regression line				
Intensity gradient,	-2.549 (-2.644, -2.390)	-2.450 (-2.577, -2.301)	-2.745 (-2.801, -2.681)	-2.676 (-2.749, -2.544)
Intercept	14.7 (14.1, 15.1)	14.3 (14.7, 14.8)	15.4 (15.2, 15.5)	14.8 (13.4, 15.1)
Explained variance, R ² , %	90.4 (88.3, 91.7)	90.8 (88.8, 92.1)	91.0 (89.6, 92.7)	92.1 (90.2, 93.4)
Average acceleration, mg	29.72 (25.79, 35.41)	30.38 (24.79, 36.96)	23.31 (11.06, 25.72)	21.38 (9.88, 24.43)
Sedentary, min ⁻ day ⁻¹	594 (542, 644)	622 (561, 673)	621 (566, 661)	692 (634, 739)
MVPA, min ⁻ day ⁻¹	111 (87, 139)	120 (87, 147)	79 (65, 86)	65 (46, 84)
Vigorous PA, min day 1	3 (1, 8)	5 (2, 13)	1 (0, 1)	1 (0, 2)
Time in PA, min day-1	377 (326, 422	358 (299, 408)	333 (284, 387)	277 (226, 336)
VO _{2peak} , mL kg ⁻¹ min ⁻¹ , [range]	30.6 (24.2, 37.8) [13.5 to 53.5]	38.2 (29.8, 46.0) [16.4 to 65.1]	16.6 (132, 18.9) [10.1 to 29.9]	22.0 (18.5, 25.1) [13.4 to 39.5]
NT-proBNP, pg/mL	103.3 (69.8, 157.9)	54.0 (35.8, 113.6)	430.4 (304.0, 571.9)	291.2 (158.5, 795.5)

Data are presented as mean (SD) or median (25th percentile, 75th percentile) unless stated otherwise. Not available data for NT-proBNP in HEALTHY n=8 and HEART n=1; for smoking status in HEART n=7. Abbreviations: NYHA, New York Heart Association; PA, physical activity; MVPA, moderate-to-vigorous PA; VO_{2peak}, peak oxygen uptake, NT-proBNP, N-terminal pro b-type natriuretic peptide.

Between-cohort differences

165

166

167

168

169

HEART had significantly lower IG (p<0.001, 95% CI: -0.185 to -0.079), AvAcc (p<0.001;

95% CI: -8.59 to -3.92 mg), MVPA (p<0.001; 95% CI: -45 to -20 min), VPA (p=0.002; 95%

170 CI: -6.1 to -1.3 min), and TPA (p<0.001; 95% CI: -80 to -33 min) than HEALTHY (see Table 171 1). HEART were more sedentary than HEALTHY (p=0.006; 95% CI: 10 to 59 min). 172 Interrelationship between accelerometer metrics and VO_{2peak} in HEALTHY and 173 174 **HEART** 175 Correlations of VO_{2peak}, IG, AvAcc, MVPA, VPA, TPA, and sedentary time are available in 176 Figure 1. *** insert Figure 1 here *** 177 178 179 Results of the explorative principal component and partial least squares analyses are 180 presented and discussed in Supplement 2. 181 182 Multiple regression models with key accelerometer parameters as independent variables and 183 VO_{2peak} as the dependent variable are presented in Table 2. In HEALTHY, model 2 (AvAcc) 184 had a better fit than model 1 (IG) (p=0.022). Model 7 (AvAcc+IG) performed better than 185 model 1 (IG) (p<0.001) and model 2 (AvAcc) (p=0.004). The best cut-point-free model 186 including AvAcc and IG (model 7) and the best cut-point-based model including VPA (model 187 4) performed similarly. 188 When combining IG as a metric of PA intensity and TPA as a surrogate of PA time (Model 5), 189 both metrics were independent predictors of VO_{2peak}. However, when including VPA and TPA 190 (model 6), there was little evidence for the latter being an independent predictor of VO_{2peak}. 191 In HEART, there was little evidence for a difference in fit between model 1 (IG), 2 (AvAcc), 192 or 7 (IG+AvAcc). Both IG and AvAcc were associated with VO_{2peak} with only IG being 193 independent of AvAcc but not vice versa. Moreover, the best model with cut-point-based 194 metric (model 3 with MVPA) performed equal to models 1 (IG) and 7 (AvAcc+IG), but was

ACCELEROMETRY REFERENCE VALUES

10

superior to model 2 (AvAcc) (p=0.012). Adding TPA to the model with IG or VPA did not significantly improve model fits (models 5&6).

*** insert Table 2 here ***

195

196

197

198

199

Table 2. Regression models for HEALTHY and HEART with peak oxygen uptake as the dependent variable.

Independent variables	Estimate	95% CI	p-value	Residual standard deviation	Adjusted R ²
HEALTHY (n=463)					
Model 1			< 0.001	5.47	0.7153
IG	10.8	(7.9 to 13.8)	< 0.001		
Model 2			< 0.001	5.27	0.7361
AvAcc	0.3	(0.24 to 0.36)	< 0.001		
Model 3			< 0.001	5.44	0.7182
MVPA	0.05	(0.04 to 0.06)	< 0.001		
Model 4			< 0.001	5.21	0.7417
VPA	0.30	(0.24 to 0.36)	< 0.001		
Model 5			< 0.001	5.41	0.7215
IG	10.34	(7.44 to 13.25)	< 0.001		
TPA	0.01	(0.005 to 0.018)	< 0.001		
Model 6			< 0.001	5.19	0.7431
VPA	0.29	(0.23 to 0.35)	< 0.001		
TPA	0.01	(-0.00 to 0.01)	0.059		
Model 7			< 0.001	5.24	0.7394
IG	4.49	(1.11 to 7.88)	0.009		
AvAcc	0.25	(0.17 to 0.32)	< 0.001		
HEART (n=67)					
Model 1			< 0.001	4.75	0.3802
IG	10.08	(3.49 to 16.67)	0.003		
Model 2			< 0.001	4.87	0.3475
AvAcc	0.26	(0.05 to 0.48)	0.016		
Model 3			< 0.001	4.73	0.3834
MVPA	0.05	(0.02 to 0.09)	0.003		
Model 4			< 0.001	5.01	0.3082
VPA	0.43	(-0.09 to 0.95)	0.107		
Model 5			< 0.001	4.76	0.3763
IG	9.33	(2.04 to 16.96)	0.009		
TPA	0.01	(-0.01 to 0.04)	0.422		
Model 6			< 0.001	5.00	0.3120
VPA	0.35	(-0.19 to 0.89)	0.203		
TPA	0.01	(-7.08 to 0.03)	0.256		
Model 7			< 0.001	4.73	0.3842
IG	7.85	(2.41 to 15.46)	0.043		
AvAcc	0.14	(-1.01 to 0.38)	0.249		

All models were adjusted for age * sex + BMI (age and BMI were modelled using restricted cubic splines). Abbreviations: AvAcc, average acceleration; HEALTHY, healthy individuals; HEART, patients with heart failure; IG, intensity gradient; MVPA, moderate to vigorous physical activity; TPA; time in physical activity; VPA, vigorous physical activity.

Reference values for healthy adults

201

202

203

204

205

206

207

Sex-specific percentile curves were created for IG, AvAcc (see Figure 2), MVPA, and VPA (see Supplementary Figure 3). Empirical data for IG and AvAcc per age decade are presented in Table 3. Data for MVPA and VPA are shown in Supplementary Table 2.

*** insert Table 3 here ***

Table 3 Empirical data for IC and AvAcc in healthy individuals stratified by ago decade and say

Table 3. Empirica	I data for IG and	AvAcc in healthy	individuals stra	tified by age dec	cade and sex.
Age decade	P ₃	P ₁₅	P ₅₀	P ₈₅	P ₉₇
IG					
		Femal	es		
20 to 29	-2.662	-2.541	-2.392	-2.244	-2.123
30 to 39	-2.713	-2.581	-2.419	-2.256	-2.124
40 to 49	-2.769	-2.627	-2.454	-2.280	-2.138
50 to 59	-2.833	-2.686	-2.505	-2.324	-2.176
60 to 69	-2.902	-2.753	-2.569	-2.385	-2.235
70 to 79	-2.973	-2.822	-2.637	-2.452	-2.301
80 to 89	-3.043	-2.890	-2.702	-2.514	-2.361
		Male	S		
20 to 29	-2.673	-2.526	-2.346	-2.167	-2.020
30 to 39	-2.682	-2.532	-2.349	-2.166	-2.016
40 to 49	-2.698	-2.546	-2.359	-2.173	-2.020
50 to 59	-2.740	-2.585	-2.394	-2.204	-2.049
60 to 69	-2.816	-2.658	-2.464	-2.270	-2.112
70 to 79	-2.921	-2.760	-2.563	-2.365	-2.204
80 to 89	-3.031	-2.867	-2.666	-2.465	-2.301
AvAcc, mg					
		Femal	es		
20 to 29	22.61	26.61	32.56	39.85	46.93
30 to 39	22.05	26.23	32.52	40.35	48.02
40 to 49	21.22	25.48	32.00	40.20	48.33
50 to 59	20.01	24.23	30.74	39.03	47.31
60 to 69	18.60	22.68	29.03	37.18	45.39
70 to 79	17.20	21.11	27.25	35.20	43.26
80 to 89	15.98	19.74	25.69	33.46	41.40

ACCELEROMETRY REFERENCE VALUES

Males					
20 to 29	18.87	23.85	31.98	42.94	54.40
30 to 39	19.61	24.79	33.24	44.63	56.54
40 to 49	20.11	25.37	33.93	45.42	57.41
50 to 59	19.98	25.03	33.18	44.03	55.27
60 to 69	18.95	23.44	30.56	39.87	49.39
70 to 79	17.11	20.78	26.48	33.75	41.05
80 to 89	15.19	18.12	22.56	28.10	33.55

Abbreviations: IG, intensity gradient; AvAcc, average acceleration per day.

*** insert Figure 2 here ***

- CRF-specific percentile curves for IG and AvAcc are available in Figure 3.
- *** insert Figure 3 here ***

We developed the application 'rawacceleration' using these reference data. It is freely available on GitHub (https://github.com/FSchwendinger/rawacceleration). Further insights into 'rawacceleration' are given in the Supplement and discussion section.

DISCUSSION

The major novel findings are IG and AvAcc yield complementary information on PA, particularly intensity, with both being important predictors of VO_{2peak} in healthy individuals and patients with heart failure. Both metrics together had similar predictive value for VO_{2peak} as the best cut-point-based metric in healthy adults. In patients with heart failure, both IG alone and IG+AvAcc together had similar predictive value as the best cut-point-based metric with IG being independent of AvAcc. Cut-point-free metrics also have the advantage of being

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

physical function).[6, 7]

13

comparable across cohorts and the most commonly used accelerometers. [6, 24] Importantly, this population-based study produced percentile curves and reference values for both cutpoint-free and traditional accelerometer metrics for healthy adults aged 20 to 89 years. This addresses the limited interpretability of the AvAcc and IG metrics by placing them into context. Our results provide generalised support for policy making. Inter-relationship between accelerometer metrics and VO_{2peak} in HEALTHY and HEART We confirmed previous findings in children and adults with type 2 diabetes suggesting AvAcc and IG provide a complementary picture of PA.[6, 7] Our study demonstrated this in healthy adults and patients with heart failure by examining correlations between accelerometer metrics. These findings are strengthened by our explorative principle component analysis. Lower communalities were seen for IG than for AvAcc or MVPA indicating IG may yield a perspective on PA not covered by other metrics. AvAcc and IG may thus provide a more complete impression of an individual's PA profile without having to rely on accelerometer cut-points. AvAcc and IG have been described to reflect PA volume and intensity, respectively.[6] Yet, correlations between TPA, VPA, IG, and AvAcc indicate that AvAcc conveys information on both PA intensity and volume. It should therefore be noted that cut-point-free metrics allow the further investigation of intensity/volume, despite their overlap, as IG captures the distribution as well as quantity of intensity. This is more difficult with cut-point-based metrics because of their categorical and population-dependent nature. Thus AvAcc and IG may be particularly appropriate when attempting to differentiate between the contribution of PA intensity and volume to CRF as well as other health parameters (e.g. body fatness, BMI,

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

IG and AvAcc together had the greatest predictive value for VO_{2peak} in healthy adults and both were independently associated, explaining a unique fraction of the variance. This is partly compliant with a study in children that estimated CRF from a shuttle-run-test.[7] IG or AvAcc as the only independent variable in the adjusted regression models was significantly associated with estimated CRF.[7] Yet, only IG remained significantly associated with CRF when AvAcc was added to the model.[7] AvAcc may consequently be more relevant in adults than in children. This is possibly due to different activity patterns with higher IG and AvAcc together with less sedentary time in children.[7] This highlights the utility of combining these two metrics to gain insight into the relative importance of volume and intensity of the PA profile which differs across populations.[6] Interestingly, TPA significantly added to model 5 also containing IG. Both intensity distribution (IG) and time spent in PA (TPA) may thus be relevant for VO_{2peak}. Notably, AvAcc captures both time and intensity of PA, thus reflecting activity volume, while IG captures the distribution of the intensity of activity. Combining IG and AvAcc thus yields complementary perspectives on PA intensity. In patients with heart failure, cut-point-free metrics had similar predictive value for VO_{2peak} as the best cut-point-based metric, MVPA. Yet, unlike in healthy adults, only IG was independent of AvAcc but not vice versa. This may reflect relatively little activity of higher intensity in these patients; it is in contrast with findings of Dawkins et al. (25) and suggests that a focus on intensity of activity, i.e. increasing the breadth of the intensity distribution, may be more important than volume if intervening in this population. This study demonstrated that IG and AvAcc are not only potentially more robust accelerometer metrics than MVPA, VPA, or TPA, as they do not rely on cut-points, but also have similar predictive value for VO_{2peak} and, in turn, indirectly for the risk of mortality and longevity.[8, 26] Indeed, Dempsey et al. (23) recently demonstrated that AvAcc and IG were

ACCELEROMETRY REFERENCE VALUES

278

279

280

281

282

283

284

independently associated with incident cardiovascular disease in participants from UK Biobank. These results and those of previous studies[6, 7] provide an evidence-based rationale that cut-point-free accelerometer metrics facilitate capture of the volume and intensity distribution of the PA profile across populations, and thus may be a viable alternative to cut-point-based outcomes in the measurement of PA.

Reference values for healthy adults

285 Our reference values and percentile curves may be pivotal to assessing the appropriateness of 286 PA on population- or individual-level and to determining the level of PA necessary for a 287 healthy lifestyle.[6] 288 IG and AvAcc at the 50th percentile are higher than in participants of the UK Biobank Study 289 aged 40 to 69 years, despite them wearing the accelerometer on their dominant hand which 290 typically elicits accelerations approximately 10% higher.[1, 27] This seems reasonable in 291 light of the good health condition (see inclusion/exclusion criteria) and the likely higher 292 CRF[12] of the COmPLETE cohort compared to the aforementioned study. Hence, our 293 reference values might be desirable benchmarks for healthy PA patterns in adults. 294 Age trajectories of IG and AvAcc were curvilinear and inverse for both sexes (see Figure 2). 295 This is in line with the accelerometer data of another Swiss adult cohort. [28] Interestingly, the 296 decline in IG and AvAcc with age seems to resemble that of CRF and muscular strength in 297 the COmPLETE cohort.[12, 29] With age, less time is spent at higher absolute intensities 298 which might be due to reduced physical functioning as apparent by lower CRF and muscular 299 strength. However, when expressed in relative terms (as % of an individual's VO_{2peak}), 300 intensity may still be high. This explanation is underpinned by questionnaire data, which may 301 also reflect the rate of perceived exertion, showing more moderate and vigorous PA in 302 individuals aged > 59 years than in 40 to 59-year-olds. [28] Moreover, the inverse relationship

ACCELEROMETRY REFERENCE VALUES

seen between accelerometer-based VPA and age seems not to be apparent in questionnaire data.[28] The proposed reference values may also be useful when PA is measured with other rawacceleration, wrist-worn accelerometers. Migueles et al. (24) found high inter-instrument reliability for four common accelerometers (GENEActiv, Movisens Move 4, ActiGraph GT3X+, and Axivity AX3) provided that raw data are processed identically. The betweendevice difference ranged between 1 (95% CI: -6 to 7) and 8 (95% CI: 1 to 15) min per day.[24] Our reference values may thus be applicable for at least the examined accelerometers (i.e. GENEActiv, Movisens Move 4, ActiGraph GT3X+, and Axivity AX3).[24] Reference values and percentile curves for cut-point-based metrics (VPA and MVPA, see Supplement: Figure 3 and Table 2) were also created. These are still commonly used and directly interpretable. Comparison to these data is however only possible when using the cutpoints by Hildebrand et al. (3) (MVPA=0.1 g and VPA=0.4 g) and processing data identically.[24] Due to the aforementioned disadvantages of cut-point-based accelerometer metrics (also discussed elsewhere[5]), cut-point-free metrics should be reported in future studies examining PA with raw-acceleration accelerometers. Importantly, the reference values for traditional metrics are specific to accelerometer data and examine the whole activity profile. They are not comparable to e.g. the PA guidelines by the WHO which focus on MVPA and were developed predominantly from self-reported data. [2, 30] This is supported by numerous studies.[31, 32] Our reference values facilitate interpretation of accelerometer-assessed PA data relative to a 'healthy norm', and may thus be an important complement to the current PA guidelines by the WHO.[30]

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

ACCELEROMETRY REFERENCE VALUES

Limitations

PA levels differ between countries.[33] Nonetheless, it seems to be desirable to promote the present reference values also in countries other than Switzerland considering the good general health of our cohort in combination with their high CRF.[12] Importantly, the present reference values are only applicable if the data are processed similarly (see Methods section and configuration file). The R-package GGIR will facilitate this process.[10] Large differences in sampling frequency of accelerometer data may impact outcomes. In a study comparing 25 Hz with 100 Hz, the lower sampling frequency led to 3.1%–13.9% lower overall acceleration values.[34] The difference may however be smaller at 50 Hz, as used in our study. Yet, sampling frequency should be considered when comparing PA metrics to the present reference values. Available algorithms may help transform PA metrics to match those obtained from higher sampling frequencies.[34] Lastly, no causation between PA and VO_{2peak} can be implied from the present study.

CLINICAL IMPLICATIONS

IG and AvAcc provide complementary information on PA, particularly the intensity distribution of the PA profile. IG and AvAcc were strongly associated with VO_{2peak} in healthy adults and patients with heart failure. These metrics are independent of accelerometer cutpoints, facilitate investigation of the relative contribution of intensity and volume of PA for a given health marker, and thus may be important parameters with regard to general health and risk for mortality and non-communicable diseases. To the best of our knowledge, this is the first study to produce reference values for IG and AvAcc for healthy adults. These reference values may be valuable to judge an individual's or a population's level of PA and facilitate cross-study comparison. The 'rawacceleration' application may be helpful for to compare

ACCELEROMETRY REFERENCE VALUES

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

authors approved the final version of the manuscript.

individual- or cohort-level data to healthy age- and sex-matched adults and translate results into meaningful outcomes in research settings and clinical practice. **Declarations** Ethics approval and consent to participate This study was approved by the Ethics Committee of North-western and Central Switzerland (EKNZ 2017–01451). All participants in this study provided informed written consent. **Consent for publication** Not applicable. Availability of data and materials The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. **Competing interests** The authors declare that they have no competing interests. **Funding** The COmPLETE study was funded by the Swiss National Science Foundation (Grant no. 182815). AVR is supported by the Lifestyle Theme of the Leicester NHR Leicester Biomedical Research Centre and NIHR Applied Research Collaborations East Midlands (ARC-EM). **Authors contributions** FS conceptualised the manuscript and wrote the original draft. FS and DI analysed and interpreted the data. JW, AST, TH, and RK conceptualised the study and defined the methods. JW and RK collected the data. FS, JW, and RK were responsible for data curation. JW, DI, RK, AVR, TH, and AST revised the manuscript. AST obtained funding for the project. All

ACCELEROMETRY REFERENCE VALUES

378 Acknowledgements 379 We are grateful for the valuable contributions of all study participants in the COmPLETE 380 study. 381 382 List of abbreviations 383 AvAcc Average acceleration 384 **CRF** Cardiorespiratory fitness 385 **ENMO** Euclidean norm minus one 386 **HEALTHY** Healthy adults 387 **HEART** Patients with heart failure 388 IG Intensity gradient 389 **MVPA** Moderate-to-vigorous physical activity 390 NT-proBNP N-terminal pro b-type natriuretic peptide 391 **NYHA** New York Heart Association 392 PA Physical activity 393 SD Standard deviation 394 **SED** Sedentary time 395 **TPA** Total physical activity 396 VO_{2peak} Peak oxygen uptake 397 **VPA** Vigorous physical activity 398 399 400 REFERENCES

- 401 Rowlands AV, Fairclough SJ, Yates TOM, Edwardson CL, Davies M, Munir F, et al.
- 402 Activity Intensity, Volume, and Norms: Utility and Interpretation of Accelerometer Metrics.
- 403 Med Sci Sports Exerc. 2019;51(11):2410-22.
- 404 2. Troiano RP, McClain JJ, Brychta RJ, Chen KY. Evolution of accelerometer methods
- 405 for physical activity research. Br J Sports Med. 2014;48(13):1019-23.

- 406 3. Hildebrand M, van Hees VT, Hansen BH, Ekelund U. Age Group Comparability of
- 407 Raw Accelerometer Output from Wrist- and Hip-Worn Monitors. Med Sci Sports Exerc.
- 408 2014;46(9):1816-24.
- 409 4. Esliger DW, Rowlands AV, Hurst TL, Catt M, Murray P, Eston RG. Validation of the
- 410 GENEA Accelerometer. Med Sci Sports Exerc. 2011;43(6):1085-93.
- 411 5. Schwendinger F, Wagner J, Infanger D, Schmidt-Trucksäss A, Knaier R.
- 412 Methodological aspects for accelerometer-based assessment of physical activity in heart
- 413 failure and health. BMC Med Res Methodol. 2021;21(1):251.
- 414 6. Rowlands AV, Edwardson CL, Davies MJ, Khunti K, Harrington DM, Yates T.
- Beyond Cut Points: Accelerometer Metrics that Capture the Physical Activity Profile. Med
- 416 Sci Sports Exerc. 2018;50(6):1323-32.
- 417 7. Fairclough SJ, Taylor S, Rowlands AV, Boddy LM, Noonan RJ. Average acceleration
- and intensity gradient of primary school children and associations with indicators of health
- 419 and well-being. J Sports Sci. 2019;37(18):2159-67.
- 420 8. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory
- 421 Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in
- 422 Healthy Men and Women: A Meta-analysis. JAMA. 2009;301(19):2024-35.
- 423 9. Wagner J, Knaier R, Infanger D, Arbeev K, Briel M, Dieterle T, et al. Functional
- 424 aging in health and heart failure: the COmPLETE Study. BMC Cardiovasc Disord.
- 425 2019;19(1):180.
- 426 10. Migueles JH, Rowlands AV, Huber F, Sabia S, van Hees VT. GGIR: A Research
- 427 Community-Driven Open Source R Package for Generating Physical Activity and Sleep
- Outcomes From Multi-Day Raw Accelerometer Data. J Meas Phys Behav. 2019;2(3):188-96.
- 429 11. van Hees VT, Gorzelniak L, Dean León EC, Eder M, Pias M, Taherian S, et al.
- 430 Separating Movement and Gravity Components in an Acceleration Signal and Implications
- 431 for the Assessment of Human Daily Physical Activity. PloS ONE. 2013;8(4):e61691.
- 432 10.1371/journal.pone.0061691.
- 433 12. Wagner J, Knaier R, Infanger D, Königstein K, Klenk C, Carrard J, et al. Novel CPET
- 434 Reference Values in Healthy Adults: Associations with Physical Activity. Med Sci Sports
- 435 Exerc. 2020;53(1):26-37.
- 436 13. R Core Team. R: A language and environment for statistical computing Vienna,
- 437 Austria: R Foundation for Statistical Computing; 2021 [Available from: https://www.R-
- 438 project.org/].
- 439 14. Kassambara A, Mundt F. Factoextra: Extract and Visualize the Results of Multivariate
- 440 Data Analyses. R Package Version 1.0.7. 2020.
- 441 15. Mevik B-H, Wehrens R. The pls Package: Principal Component and Partial Least
- 442 Squares Regression in R. J Stat Softw. 2007;18(2):1-23.
- 443 16. Harrell FE, Jr. Regression modeling strategies. 2 ed: Springer International
- 444 Publishing; 2015.
- 445 17. Vuong QH. Likelihood Ratio Tests for Model Selection and Non-Nested Hypotheses.
- 446 Econometrica. 1989;57(2):307-33.
- 447 18. Stasinopoulos DM, Rigby RA. Generalized Additive Models for Location Scale and
- 448 Shape (GAMLSS) in R. J Stat Softw. 2007;23(7):1-46.
- 449 19. Stasinopoulos MD, Rigby, R.A., Heller, G.Z., Voudouris, V., De Bastiani, F. . Flexible
- 450 Regression and Smoothing: Using GAMLSS in R. 1 ed: Chapman and Hall/CRC; 2017.
- 451 20. Eilers PHC, Marx, B. D. Practical smoothing. The joys of P-splines: Cambridge
- 452 University Press; 2021.
- 453 21. van Buuren S, Fredriks M. Worm plot: a simple diagnostic device for modelling
- 454 growth reference curves. Stat Med. 2001;20(8):1259-77.

- 455 22. Chang W, Cheng J, Allaire J, Xie Y, McPherson J. Shiny: web application framework
- 456 for R. R package version. 2017;1(5):2017.
- 457 23. Dempsey PC, Rowlands AV, Strain T, Zaccardi F, Dawkins NP, Razieh C, et al.
- 458 Physical activity volume, intensity and incident cardiovascular disease. Eur Heart J.
- 459 2022:43(46):4789-4800.
- 460 24. Migueles JH, Molina-Garcia P, Torres-Lopez LV, Cadenas-Sanchez C, Rowlands AV,
- 461 Ebner-Priemer UW, et al. Equivalency of four research-grade movement sensors to assess
- 462 movement behaviors and its implications for population surveillance. Sci Rep.
- 463 2022;12(1):5525. 10.1038/s41598-022-09469-2.
- Dawkins NP, Yates T, Edwardson CL, Maylor B, Henson J, Hall AP, et al. Importance
- of Overall Activity and Intensity of Activity for Cardiometabolic Risk in Those with and
- Without a Chronic Disease. Med Sci Sports Exerc. 2022;54(9):1582-90.
- 467 26. Mok A, Khaw K-T, Luben R, Wareham N, Brage S. Physical activity trajectories and
- 468 mortality: population based cohort study. BMJ. 2019;365:12323. 10.1136/bmj.12323.
- 469 27. Buchan DS, Boddy LM, McLellan G. Comparison of Free-Living and Laboratory
- 470 Activity Outcomes from ActiGraph Accelerometers Worn on the Dominant and Non-
- Dominant Wrists. Meas Phys Edu Exerc Sci. 2020;24(4):247-57.
- 472 28. Wanner M, Hartmann C, Pestoni G, Martin BW, Siegrist M, Martin-Diener E.
- 473 Validation of the Global Physical Activity Questionnaire for self-administration in a
- 474 European context. BMJ Open Sport Exerc Med. 2017;3(1):e000206. 10.1136/bmjsem-2016-
- 475 000206.
- 476 29. Lichtenstein E, Wagner J, Knaier R, Infanger D, Roth R, Hinrichs T, et al. Norm
- 477 Values of Muscular Strength Across the Life Span in a Healthy Swiss Population: The
- 478 COmPLETE Study. Sports Health. 2022. 10.1177/19417381221116345.
- 479 30. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World
- 480 Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J
- 481 Sports Med. 2020;54(24):1451-62.
- 482 31. Tucker JM, Welk GJ, Beyler NK. Physical activity in U.S.: adults compliance with the
- Physical Activity Guidelines for Americans. Am J Prev Med. 2011;40(4):454-61.
- 484 32. Schuna JM, Jr., Johnson WD, Tudor-Locke C. Adult self-reported and objectively
- 485 monitored physical activity and sedentary behavior: NHANES 2005-2006. Int J Behav Nutr
- 486 Phys Act. 2013;10:126. 10.1186/1479-5868-10-126.
- 487 33. Bauman A, Ainsworth BE, Sallis JF, Hagströmer M, Craig CL, Bull FC, et al. The
- 488 Descriptive Epidemiology of Sitting: A 20-Country Comparison Using the International
- 489 Physical Activity Questionnaire (IPAQ). Am J Prev Med. 2011;41(2):228-35.
- 490 34. Small S, Khalid S, Dhiman P, Chan S, Jackson D, Doherty A, et al. Impact of
- 491 Reduced Sampling Rate on Accelerometer-Based Physical Activity Monitoring and Machine
- Learning Activity Classification. J Meas Phys Behav. 2021;4(4):298-310.

495 Figure legends

493

494

- 496 **Figure 1.** Spearman correlations of average acceleration (AvAcc), intensity gradient (IG), moderate-to-vigorous
- 497 physical activity (MVPA), sedentary time (SED), time in physical activity (TPA), peak oxygen uptake
- 498 (VO2peak), and vigorous physical activity (VPA) for healthy individuals (HEALTHY) and patients with heart
- failure (HEART), respectively. Non-significant correlations are crossed.

ACCELEROMETRY REFERENCE VALUES

Figure 2. Percentile curves for intensity gradient (A & B) and average acceleration (C & D) in relation to age in healthy adults. The left column shows data for females and the right column for males. Mean values of IG and AvAcc of other cohorts were plotted to highlight the potential of the reference curves for comparability across studies and between devices. Data by Rowlands et al. (1): pre- and post-menopausal women (n_{pre}=1218, n_{post}=1316; device: Axivity). Dempsey et al. (23): participants of the UK Biobank study (females, n = 51,509; males, n=36,903, device: Axivity, dominant wrist). Our data of patients with heart failure (HEART; device: GENEActiv) were also plotted.

Figure 3. Percentile curves for intensity gradient (A & B) and average acceleration (C & D) in relation to VO_{2peak} in healthy adults stratified by sex. The left column shows data for females and the right column for males. Abbreviations: VO_{2peak}, peak oxygen uptake.





